CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008981
Abstract: Key Points • Most patients with refractory B-ALL could achieve remission with a single infusion of CAR T cells.• Survival probability is excellent for patients who relapsed >6 months posttransplant and poor for patients who… read more here.
Keywords: effective therapy; cd19 car; car; cells effective ... See more keywords